Pittenger & Anderson Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Pittenger & Anderson Inc’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-162	Closed	-$115K	–	447
2024 Q4	$115K	Hold	162	–	–	﹤0.01%	252
2024 Q3	$170K	Hold	162	–	–	0.01%	239
2024 Q2	$170K	Sell	162 -13	-7%	-$12.6K	0.01%	229
2024 Q1	$168K	Hold	175	–	–	0.01%	233
2023 Q4	$154K	Hold	175	–	–	0.01%	234
2023 Q3	$144K	Hold	175	–	–	0.01%	213
2023 Q2	$126K	Hold	175	–	–	0.01%	229
2023 Q1	$144K	Hold	175	–	–	0.01%	225
2022 Q4	$126K	Sell	175 -25	-13%	-$18.4K	0.01%	229
2022 Q3	$138K	Hold	200	–	–	0.01%	217
2022 Q2	$118K	Hold	200	–	–	0.01%	229
2022 Q1	$140K	Hold	200	–	–	0.01%	232
2021 Q4	$126K	Buy	+200	New	+$123K	0.01%	239

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pittenger & Anderson Inc's REGN Position: Q1 2025 in Review

Pittenger & Anderson Inc sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 162 shares — an estimated $115K sold.

Pittenger & Anderson Inc first reported a position in REGN in Q4 2021 and held it in 13 quarters. The position peaked at $170K in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Pittenger & Anderson Inc reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Pittenger & Anderson Inc sold 162 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $115K.
Pittenger & Anderson Inc first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 13 quarters.
Pittenger & Anderson Inc's Regeneron Pharmaceuticals position peaked at $170K in Q3 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2025, filed 1 May 2025.